...
首页> 外文期刊>Pharmacoepidemiology and drug safety >Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial.
【24h】

Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial.

机译:在SKICAP-AK试验中,非甾体类抗炎药对非黑素瘤皮肤癌发生率的影响。

获取原文
获取原文并翻译 | 示例

摘要

Recent studies link the prostaglandin metabolic pathway to skin carcinogenesis expanding possibilities that cyclooxygenase (COX) inhibitors may be utilized in non-melanoma skin cancer (NMSC) chemoprevention. Using data from a study of the efficacy of retinol supplementation on incidence of NMSC, we sought to determine the role of non-steroidal anti-inflammatory drugs (NSAIDs) in NMSC development. Cox proportional hazards models describe the relationship between NSAID use and time to first squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) among participants categorized by use pattern: continuous users (use for length of study duration), new users (use for less than study duration), and non-users. For SCC and BCC, there was a statistically significant protective effect for participants who reported use for less than the study duration (HR = 0.49, 95%CI 0.28-0.87 and HR = 0.43, 95%CI 0.25-0.73, respectively). Categorical examination of NSAIDs (aspirin (ASA) vs. non-ASA NSAIDs) showed significanteffects for BCC among those using non-ASA NSAIDs for less than the study duration (HR = 0.33, 95%CI 0.13-0.80). For SCC and BCC, NSAID use of shorter duration and potentially more recent, was more protective than longer duration of use. These results are counter to the idea that longer duration of NSAID use is more protective. Additional investigations are needed into the role NSAIDs play in the chemoprevention of NMSC.
机译:最近的研究将前列腺素代谢途径与皮肤癌发生联系起来,从而扩大了环氧合酶(COX)抑制剂可用于非黑素瘤皮肤癌(NMSC)化学预防的可能性。使用来自视黄醇补充对NMSC发生率的功效研究的数据,我们试图确定非甾体抗炎药(NSAIDs)在NMSC发育中的作用。 Cox比例风险模型描述了按使用方式分类的参与者中,NSAID使用与发生第一鳞状细胞癌(SCC)或基底细胞癌(BCC)的时间之间的关系:连续使用者(用于研究持续时间),新使用者(用于少于学习时间)和非用户。对于SCC和BCC,报告使用时间少于研究持续时间的参与者具有统计学上的显着保护作用(HR分别为0.49、95%CI 0.28-0.87和HR = 0.43、95%CI 0.25-0.73)。对NSAID的分类检查(阿司匹林(ASA)与非ASA NSAIDs)显示,在使用非ASA NSAID的患者中,对于BCC的显着影响少于研究持续时间(HR = 0.33,95%CI 0.13-0.80)。对于SCC和BCC,使用NSAID的持续时间较短且可能更近期,比使用较长的持续时间更具保护性。这些结果与长期使用NSAID更具保护性这一想法背道而驰。还需要进一步研究NSAID在NMSC化学预防中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号